Danaher Co. (NYSE:DHR – Get Free Report) SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Danaher Trading Up 1.5 %
Shares of NYSE:DHR traded up $4.04 during trading on Friday, reaching $274.13. 2,810,107 shares of the stock were exchanged, compared to its average volume of 2,922,034. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.43. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $277.72. The firm has a market cap of $197.98 billion, a price-to-earnings ratio of 45.78, a price-to-earnings-growth ratio of 4.11 and a beta of 0.83. The firm’s 50-day moving average price is $254.99 and its 200 day moving average price is $248.82.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.6 earnings per share for the current fiscal year.
Danaher Dividend Announcement
Analysts Set New Price Targets
Several research analysts recently weighed in on the stock. Stifel Nicolaus boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday. Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday. SVB Leerink boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.88.
Read Our Latest Stock Report on DHR
Hedge Funds Weigh In On Danaher
Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Danaher in the 4th quarter valued at approximately $1,752,382,000. Vanguard Group Inc. raised its position in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Swedbank AB acquired a new stake in shares of Danaher during the 1st quarter valued at approximately $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after acquiring an additional 2,096,038 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Why Are These Companies Considered Blue Chips?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Conference Calls and Individual Investors
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Trading Halts Explained
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.